| Nov 3 2023 |
FDA LDT Webinar Serves as a Reminder to Industry to Submit Comments on the Proposed Rule |
Epstein Becker & Green, P.C. |
| Nov 3 2023 |
Medical Marketer Convicted of $55 Million Fraud Scheme |
ArentFox Schiff LLP |
| Nov 2 2023 |
FDA Proposes Rule to Prohibit Brominated Vegetable Oil in Food |
Keller and Heckman LLP |
| Nov 2 2023 |
Diagnosing Health Care Podcast – Episode 71: Dietary Supplements – Navigating the Regulatory Maze [Podcast] |
Epstein Becker & Green, P.C. |
| Nov 1 2023 |
PFAS in Consumer Products: CPSC Requests Input |
Keller and Heckman LLP |
| Nov 1 2023 |
FDA Issued a Proposed Rule to Amend Prior Notice Regulation |
Keller and Heckman LLP |
| Nov 1 2023 |
PFAS Consumer Fraud Lawsuit Update: New Protein Supplement Case In NY |
CMBG3 Law |
| Oct 31 2023 |
FDA Seeks Comments on Revised Draft Guidance for Communicating Scientific Information on Unapproved Uses of Approved/Cleared Medical Products |
Keller and Heckman LLP |
| Oct 31 2023 |
The Haunting in the Cornfield: Relators’ Qui Tam Claim Confirmed Dead by the Eighth Circuit |
Bradley Arant Boult Cummings LLP |
| Oct 31 2023 |
This is the End: Alabama Medical Cannabis Commission Sets End Game Scenario – Will it Work? |
Bradley Arant Boult Cummings LLP |
| Oct 31 2023 |
FDA: New Draft Guidance on Communication of Unapproved Uses of Approved or Cleared Medical Products |
Foley & Lardner LLP |
| Oct 30 2023 |
Alcohol Industry M&A: Common Pitfalls for Founders (and Avoiding Them) Part One: Formulas and Processes |
McDermott Will & Schulte LLP |
| Oct 30 2023 |
District Courts Apply Ninth Circuit Precedent to Dismiss Deceptive Labelling Claims |
Foley & Lardner LLP |
| Oct 30 2023 |
Guidance from FDA Clarifies a Key Issue for Industry: Non-Promotional Presentations About Unapproved Uses of Medical Products Can Be Produced by the Products’ Sponsors Without Violating Off-Label Rules |
Mintz |
| Oct 30 2023 |
High Protections on Information Relating to Employees’ Cannabis Use |
Sheppard, Mullin, Richter & Hampton LLP |
| Oct 30 2023 |
Fast 5: Five Quick Regulatory Takeaways for Pharmaceutical Companies |
ArentFox Schiff LLP |
| Oct 30 2023 |
FDA’s New Enforcement Policy: A Win for Remote Patient Monitoring and Remote Therapeutic Monitoring Manufacturers |
Foley & Lardner LLP |
| Oct 30 2023 |
Study Finds One-Third of Chocolate Contains High Levels of Heavy Metals |
Keller and Heckman LLP |
| Oct 30 2023 |
Compensation for Food Handler Certification in California |
Jackson Lewis P.C. |
| Oct 27 2023 |
HRSA Issues Notice Confirming 340B Registration Requirement |
McDermott Will & Schulte LLP |
| Oct 27 2023 |
New Antidumping and Countervailing Petitions on Frozen Warmwater Shrimp from Ecuador, India, Indonesia, and Vietnam |
ArentFox Schiff LLP |
| Oct 26 2023 |
GT Legal Food Talk Episode 22: Supplementing Your Pet’s Lifestyle with Bill Bookout and the National Animal Supplement Council |
Greenberg Traurig, LLP |
| Oct 26 2023 |
FDA Issues New Warning Regarding Compounded Ketamine |
Foley & Lardner LLP |
| Oct 26 2023 |
Big Law Redefined: Episode 9 | Beware, New Beauty Brands! |
Greenberg Traurig, LLP |
| Oct 25 2023 |
NanoHarmony Publishes White Paper on OECD Test Guideline Development |
Bergeson & Campbell, P.C. |
| Oct 25 2023 |
Connecticut Follows in the Footsteps of Other Jurisdictions Requiring Registration of Pharmaceutical Representatives |
Sheppard, Mullin, Richter & Hampton LLP |
| Oct 25 2023 |
California Bans Several FDA-Authorized Food Additives; New York May Soon Follow |
ArentFox Schiff LLP |
| Oct 25 2023 |
DEA Further Extends Flexibilities for Controlled-Substance Prescribing Via Telemedicine |
McDermott Will & Schulte LLP |
| Oct 25 2023 |
FDA Publishes FY 2021 Pesticide Residue Report |
Keller and Heckman LLP |
| Oct 24 2023 |
Congress May Have a Vision for Psychedelic Regulation in the US |
Epstein Becker & Green, P.C. |
| Oct 24 2023 |
Stocking Naloxone in the Workplace: What Employers Need to Consider |
Ogletree, Deakins, Nash, Smoak & Stewart, P.C. |
| Oct 24 2023 |
Telehealth Update: DEA Extends Flexibility in Prescribing Controlled Substances via Telehealth Through 2024 |
Mintz |
| Oct 24 2023 |
FDA Updates Guidance Regarding Scientific Communications to HCPs about Unapproved Uses of Approved/Cleared Medical Devices and Drugs |
Nelson Mullins |
| Oct 24 2023 |
DEA Issues Second Temporary Extension of COVID-19 Telemedicine Prescribing Flexibilities, Through 2024 |
Epstein Becker & Green, P.C. |
| Oct 24 2023 |
DEA Further Extends COVID-19 Telemedicine Prescribing Flexibilities through December 31, 2024 |
Robinson & Cole LLP |
